TIPS to decide whether to prescribe aspirin for the primary prevention of cardiovascular events in chronic kidney disease

Pavel S Roshanov; Amit X Garg

doi:10.1016/j.kint.2022.10.018

TIPS to decide whether to prescribe aspirin for the primary prevention of cardiovascular events in chronic kidney disease

Kidney Int. 2023 Feb;103(2):261-263. doi: 10.1016/j.kint.2022.10.018.

Authors

Pavel S Roshanov¹, Amit X Garg²

Affiliations

¹ Department of Medicine, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. Electronic address: pavel.roshanov@lhsc.on.ca.
² Department of Medicine, Western University, London, Ontario, Canada; Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.

PMID: 36681456
DOI: 10.1016/j.kint.2022.10.018

Abstract

Aspirin effectively prevents subsequent cardiovascular events. A post hoc subgroup analysis of the International Polycap Study 3 (TIPS-3) trial suggests that patients with chronic kidney disease might also benefit from aspirin for primary prevention. We consider the merits of doing so in practice.

Publication types

Clinical Trial
Comment

MeSH terms

Aspirin / adverse effects
Cardiovascular Diseases* / etiology
Cardiovascular Diseases* / prevention & control
Humans
Platelet Aggregation Inhibitors / adverse effects
Primary Prevention
Renal Insufficiency, Chronic* / complications

Substances

Aspirin
Platelet Aggregation Inhibitors